WHO
REGULATORY UPDATE
Microlab’s Abacavir (as sulfate)/Dolutegravir (as sodium)/Lamivudine Dispersible Tablet, 60 mg/5 mg/30 mg prequalified
Published: 5/25/2026Detected: 4/10/2026
Summary preview
WHO Prequalification Unit (PQT) added the below new product to its prequalified list: • HA809 Abacavir (as sulfate)/Dolutegravir (as sodium)/Lamivudine Dispersible Tablet, 60 mg/5 mg/30 mg – Microlabs - INDIA.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from WHO.